<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964571</url>
  </required_header>
  <id_info>
    <org_study_id>AOI GCS MERRI/2017/CDR-01</org_study_id>
    <nct_id>NCT03964571</nct_id>
  </id_info>
  <brief_title>Human and Bacterial Protease Activity as Prognostic Tool of Foot Infections in Diabetic Patients</brief_title>
  <acronym>CHEK BAC</acronym>
  <official_title>Human and Bacterial Protease Activity as Prognostic Tool of Foot Infections in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will establish whether human and bacterial protease activity can aid therapeutic
      decision-making, including targeted treatments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in size of wound</measure>
    <time_frame>From Day 0 to week 4</time_frame>
    <description>% change in surface area of wound; traced on OpSite Flexigrid ® film</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of elevated protease activity in foot wound</measure>
    <time_frame>Day 0</time_frame>
    <description>Binary Yes/No; WOUNDCHEK™ Protease Status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of elevated protease activity in foot wound</measure>
    <time_frame>Day 14</time_frame>
    <description>Binary Yes/No; WOUNDCHEK™ Protease Status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of elevated protease activity in foot wound</measure>
    <time_frame>Day 28</time_frame>
    <description>Binary Yes/No; WOUNDCHEK™ Protease Status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of bacterial protease activity in foot wound</measure>
    <time_frame>Day 0, 14 and 28</time_frame>
    <description>Binary Yes/No; WOUNDCHEK™ Bacterial Status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of bacterial protease activity in foot wound</measure>
    <time_frame>Day 14</time_frame>
    <description>Binary Yes/No; WOUNDCHEK™ Bacterial Status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of bacterial protease activity in foot wound</measure>
    <time_frame>Day 28</time_frame>
    <description>Binary Yes/No; WOUNDCHEK™ Bacterial Status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical exam of wound</measure>
    <time_frame>Day 0</time_frame>
    <description>Classification as either infection or colonization according to Infectious Diseases Society of America classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of pathogenic bacteria in wound</measure>
    <time_frame>Day 0</time_frame>
    <description>Wound swabs cultured and bacteria identified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of pathogenic bacteria in wound</measure>
    <time_frame>Day 14</time_frame>
    <description>Wound swabs cultured and bacteria identified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of pathogenic bacteria in wound</measure>
    <time_frame>Day 28</time_frame>
    <description>Wound swabs cultured and bacteria identified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in size of wound</measure>
    <time_frame>From Day 0 to Week 2</time_frame>
    <description>% change in surface area of wound; traced on OpSite Flexigrid ® film</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Diabetic Foot Infection</condition>
  <arm_group>
    <arm_group_label>Diabetic foot patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>WOUNDCHEK</intervention_name>
    <description>fluid swab of wound and measurement of wound onto film</description>
    <arm_group_label>Diabetic foot patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be a member or beneficiary of a health insurance plan

          -  The patient has been informed about the study objectives and purpose and their rights
             as a patient

          -  The patient is being treated in the Diabetes and Infectious Disease Department

          -  The patient has a chronic foot and/or heel wound classified as Grade 1-3 according to
             the Infectious Diseases Society of America.

        Exclusion Criteria:

          -  The subject is participating in another category I interventional study, or has
             participated in another category I interventional trial in the previous 3 months, or
             is in a period of exclusion determined by a previous study

          -  The subject refuses to sign the consent

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship

          -  The patient is pregnant or breastfeeding

          -  The patient has chronic foot and/or heel wound classified as Grade 4 according to the
             Infectious Diseases Society of America

          -  Patient with critical ischemia defined by PSGo &lt;50 mmHg or PSCh &lt;70 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe Lavigne</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Dunyach-Remy</last_name>
    <phone>04.66.68.32.02</phone>
    <email>catherine.dunyach-remy@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH d'Alès</name>
      <address>
        <city>Alès</city>
        <zip>30100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibault Fraisse, MD</last_name>
      <phone>04 66 78 33 33</phone>
    </contact>
    <investigator>
      <last_name>Thibault Fraisse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Bagnols sur Céze</name>
      <address>
        <city>Bagnols-sur-Cèze</city>
        <zip>30200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Crouzet</last_name>
      <phone>04.66.79.78.07</phone>
    </contact>
    <investigator>
      <last_name>Julien Crouzet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariane Sultan</last_name>
      <phone>04 67 60 46 50</phone>
    </contact>
    <investigator>
      <last_name>Ariane Sultan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Pochic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine Avignon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Dunyach-Remy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe Lavigne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Marie Guedj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Gilly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert Sotto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Lechiche, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie Verbeke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Schuldiner Sophie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Focal Infection</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

